Efficient induction of an antigen-specific, T helper type 1 immune response by interleukin-12-secreting fibroblasts

Immunology

Volumn 100, Issue 2, 2000, Pages 203-208

  Kim, T S ^a   Kim, K M ^a   Shin, B A ^b   Hwang, S Y ^c  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 4; OVALBUMIN; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; CELL STRAIN 3T3; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FIBROBLAST; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; TH1 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FIBROBLASTS; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; OVALBUMIN; TH1 CELLS; TRANSFECTION;

EID: 0034121865     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2000.00038.x     Document Type: Article

References (32)

1. 1. MOSMANN T.R. (1991) Cytokine secretion phenotypes of TH cells: how many subsets, how much regulation?. Res Immunol 142, 9.
2. + T cell responses: the alternative approaches. Annu Rev Immunol 15, 297.
3. 3. ROMAGNANI S. (1996) Th1 and Th2 in human diseases. Clin Immunol Immunopathol 80, 225.
4. 4. D'ELIOS M. & DEL PRETE G. (1998) Th1/Th2 balance in human disease. Transplant Proc Ther 30, 2373.
5. 5. ELSE K.J. & FINKELMAN F.D. (1998) Intestinal nematode parasites, cytokines and effector mechanisms. Int J Parasitol 28, 1145.
6. 6. HAYASHI M., MARTINEZ O.M., GARCIA-KENNEDY R., SO S., ESQUIVEL C.O. & KRAMS S.M. (1995) Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation 60, 1533.
7. 7. LAFAILLE J.J. (1998) The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 9, 139.
8. 8. GREWE M., BRUUNZEEL-KOOMEN C.A., SCHOPF E. et al. (1998) A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 19, 359.
9. 9. O'GARRA A. (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8, 275.
10. 10. TRINCHIERI G. (1998) Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16, 365.
11. 11. WYNN T.A., ELTOU I., OSWALD I.P., CHEEVER A.W. & SHER A. (1994) Endogenous interleukin-12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med 179, 1551.
12. 12. COOPER A.M., MAGRAM J., FERRANTE J. & ORME I.M. (1997) Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 186, 39.
13. 13. AFONSO L.C., SCHARTON T.M., VIEIRA L.Q., MYSOCKA M., TRINCHIERI G. & SCOTT P. (1994) The adjuvant effect of IL-12 in a vaccine against Leishmania major. Science 263, 235.
14. 14. REMPEL J.D., WANG M. & HAYGLASS K.T. (1997) In vivo IL-12 administration induces profound by transient commitment to T helper cell type 1-associated patterns of cytokine and antibody production. J Immunol 159, 1490.
15. 15. CHOUGNET C. & SHEARER G.M. (1996) Potential clinical applications of interleukin-12. Curr Opin Hematol 3, 216.
16. 16. MOTZER R.J., RAKHIT A., SCHWARTZ L.H. et al. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4, 1183.
17. 17. KIM T.S. & COHEN E.P. (1994) Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54, 2531.
18. 18. KANG B.Y., CHUNG S.W., LIM Y.S. et al. (1999) Interleukin-12-secreting fibroblasts are more efficient than free recombinant interleukin-12 in inducing the persistent resistance to Mycobacterium avium infection. Immunology 97, 474.
19. 19. TAHARA H., ZEH H.J. III, STORKUS W.J. et al. (1994) Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54, 182.
20. 20. OPENSHAW P., MURPHY E., HOSKEN N.A. et al. (1995) Heterogeneity of intracellular cytokine synthesis at the single cell level in polarized T helper 1 and helper 2 populations. J Exp Med 182, 1357.
21. 21. KIM T.S., DEKYUYFF R.H., RUPPER MAECKER H.T., LEVY S. & UMETSU D.T. (1997) An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 158, 4137.
22. 22. COLIGAN J.E., KRUISBECK A.M., MARGULIES D.H., SHEVACH E.M. & STROBER W. (1995). Current Protocols in Immunology. Wiley Press, London.
23. 23. GRUN J.L. & MAURER P.H. (1989) Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121, 134.
24. 24. YANG X. & HAYGLASS K.T. (1993) Allergen-dependent induction of interleukin-4 synthesis in vivo. Immunology 78, 74.
25. 25. MURPHY E., SHIBUYA K., HOSKEN N. et al. (1996) Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 183, 901.
26. 26. ZITVOGEL L., TAHARA H., ROBBINS P.D. et al. (1995) Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155, 1393.
27. 27. ARUGA A., ARUGA E. & CHANG A.E. (1997) Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res 57, 3230.
28. 28. TUTING T., GAMBOTTO A., BAAR J. et al. (1997) Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther 4, 1053.
29. 29. MARSUMOTO G., SUNAMURA M., SHIMAMURA H. et al. (1999) Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model. Surgery 125, 257.
30. 30. SOBOL R.E., SHAWLER D.L., CARSON C. et al. (1999) Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a phase I study. Clin Cancer Res 5, 2359.
31. 31. KOBAYASHI K., NAKATA N., KAI M., KASAMA T., HANYUDA Y. & HATANO Y. (1997) Decreased expression of cytokines that induced type 1 helper T cell/interferon-gamma responses in genetically susceptible mice infected with Mycobacterium avium. Clin Immunol Immunopathol 85, 112.
32. 32. NABORS G.S., AFONSO L.C.C., FARRELL J.P. & SCOTT P. (1995) Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci USA 92, 3142.